期刊
CANCER PREVENTION RESEARCH
卷 3, 期 1, 页码 8-11出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/1940-6207.CAPR-09-0248
关键词
-
类别
资金
- DIVISION OF CANCER PREVENTION AND CONTROL [N01CN085183] Funding Source: NIH RePORTER
- NATIONAL CANCER INSTITUTE [P30CA013148, R01CA138998] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [P30AR050948] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES [R01ES015323, R21ES017494] Funding Source: NIH RePORTER
- NCI NIH HHS [N01 CN085183, N01 CN043300, P30 CA013148, R01 CA138998] Funding Source: Medline
- NIAMS NIH HHS [P30 AR050948-05, P30 AR050948] Funding Source: Medline
- NIEHS NIH HHS [R21 ES017494, R21 ES017494-01, R01 ES015323-04, R01 ES015323] Funding Source: Medline
Bailey et al. report in this issue of the journal (beginning on page 35) one of the first successful trials of basal cell carcinoma (BCC) prevention. Oral alpha-difluoromethyl-dl-ornithine (DFMO) reduced new BCCs in patients with a prior history of nonmelanoma skin cancer. DFMO is an inhibitor of ornithine decarboxylase, a key enzyme in the polyamine biosynthetic pathway. This perspective on Bailey et al. discusses our knowledge of the contribution of polyamines to BCC pathogenesis, how this knowledge advanced the development of a new method to prevent BCCs, and prospects for future studies of DFMO in BCC prevention. Cancer Prev Res; 3(1); 8-11. (c) 2010 AACR.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据
分享论文
